Studies of neutralising antibodies to SV40 in human sera

Return to Vaccination News Home Page

Subscribe to the Vaccination NewsLetter

View past & current Scandals (columns by Sandy Mintz)

http://www3.interscience.wiley.com/cgi-bin/abstract/104530558/START

Online ISSN: 1096-9071 Print ISSN: 0146-6615
Journal of Medical Virology
Volume 70, Issue 3, 2003. Pages: 490-495

Published Online: 6 May 2003

Studies of neutralising antibodies to SV40 in human sera

P. Minor^{1 *}, P. Pipkin¹, Z. Jarzebek², W. Knowles³

¹Division of Virology, National Institute for Biological Standards and Control, Herts, United Kingdom
²Department of Virology, National Institute of Hygiene, Warsaw, Poland
³Public Health Laboratory Service, London, United Kingdom

^*Correspondence to P. Minor, Division of Virology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Herts, United Kingdom.

Keywords

SV40 serology • polio vaccine BK, JC

Abstract

It has been suggested that the low levels of antibody to the simian polyoma virus SV40 found in human sera may be linked to the use of polio vaccines. Panels of sera from areas of the world with different vaccination histories were examined to see if consistent differences could be identified. In a total of 2,054 sera from the United Kingdom, 692 from Africa and 923 from Poland taken between 1985 and 1997, the seroprevalence was generally between 3 and 5%, although exceptionally one collection from Morocco had a prevalence of 100%, and one from Poland of 0.4%. The seroprevalence showed no obvious age-dependent increase and titres were low compared to post infection animal sera. The results are consistent with previous studies and reveal no general geographically based differences related to possible differences in vaccination history, but the origin of the SV40 antibody in human sera remains to be established. J. Med. Virol. 70:490-495, 2003. © 2003 Wiley-Liss, Inc.

Accepted: 9 January 2003

Return to Vaccination News Home Page

DISCLAIMER: All information, data, and material contained, presented, or provided here is for general information purposes only and is not to be construed as reflecting the knowledge or opinions of the publisher, and is not to be construed or intended as providing medical or legal advice. The decision whether or not to vaccinate is an important and complex issue and should be made by you, and you alone, in consultation with your health care provider.